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Accepted 24 November 2009A 27-year-old woman, gravida 3, para 0, with a gestational
age of 7 weeks, visited our hospital for occasional vaginal
bleeding. In the past 12 months, she had suffered from two
miscarriages of 6 and 8 gestational weeks, respectively. All of
the gynecological and autoimmune surveys were within
normal range. Under the suspicion of habitual abortion,
prednisolone tablets (10 mg/d) and progesterone natural-M
capsule (200 mg/d) were prescribed, as well as bed rest was
suggested. Unfortunately, she suffered from persistent vaginal
bleeding without abdominal pain 4 weeks after first inter-
view (11 gestational weeks). The repetitive transabdominal
ultrasound identified normal fetal heart activities and signifi-
cant subchorionic hematoma sized as 38 mm 12 mm. After
admission, initial tocolytic treatment consisted mainly of
intramuscular progesterone 100 mg/d and oral prednisolone
20 mg/d. Then, she had not experienced significant bleeding
for the subsequent few weeks until the gestational age of
15 weeks and 5 days. She suffered from sudden severe lower
abdominal cramping pain and profound vaginal bleeding.
Regular uterine contractions were noted by tocography. A
b-agonist (Ritodrine; Chinese Chemistry pharmaceutical
factory, Taiwan) was added. However, the patient experienced
severe side effects of Ritodrine, in particular, palpitation and
tachycardia. Hence, Ritodrine was tapered and then ceased.
Unfortunately, the symptoms got worse, which included fresh
vaginal bleeding, severe lower abdominal pain, frequent sore-
ness of back, and strong bearing-down sensations. Regular
uterine contractions with moderate pressure were noted. Under
ultrasonic examination, the subchorionic hematoma became
extended, which was measured as 52 mm 33 mm (Fig. 1).
One new intraplacental hematoma measuring 31 mm 13 mm
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failed because of profound vaginal bleeding and great discom-
fort. Abortion seemed inevitable. After extended counseling, the
patient and her family wanted to try any effort to preserve the
pregnancy. Under this circumstance, we decided to administer
oxytocin antagonist, atosiban, immediately.
The standard protocol for atosiban was administered as
follows: an initial bolus of 6.75 mg, followed by 300 mg/min
for 3 hours and 100 mg/min for the next 37 hours (a total of 40
hours). The concomitant medication was magnesium sulfate
33.3 mg/min (2 g/h). After bolus injection, she only experi-
enced light contractions, and the magnitude of uterine
contractions subsided gradually (Fig. 2). The patient felt much
relief from the pain and bearing-down sensation. The amount
of fresh blood from vagina decreased significantly.
We discontinued atosiban 40 hours after the first dose. She did
not experience significant vaginal bleeding, and there was low
abdominal cramping. The following tocolytic therapy wasFig. 1. Hematoma after severe and regular uterine contractions.
cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 2. (A) Regular and significant uterine contractions were noted before the administration of atosiban. (B) The uterine contractions subsided after the
administration of atosiban. FMP ¼ fetal monitoring programme; Toco ¼ Tocolysis.
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patient was discharged at 29 weeks and 6 days of gestation under
relatively stable condition. Six weeks later, she began to expe-
rience regular uterine contractions and rupture of membrane
at 36 weeks’ gestation. Within 6 hours, a girl baby weighting
2,130 g was vaginally delivered. The Apgar scores were 6 and
7 after 1 minute and 5 minutes, respectively. Mild subcostal
retraction, nasal flaring, and grunting were noticed. Under the
diagnosis of Grade I respiratory distress syndrome, the baby
received intensive neonatal care without ventilator for 2 days.
The postnatal care was smooth, and she was discharged 3 weeks
later. The girl was quite healthy at the age of 8 months.
Discussion
To our knowledge, this is the case of the earliest-gestational-
age woman receiving successful anti-oxytocin therapy. This
case illustrates the possibility of treatment with atosiban to
avert severe threatened abortion in the early second trimester.
b2-Agonists have been the mainstay of tocolytic treatment
over the past few decades, during which time they have been
the only drugs licensed for this use worldwide. However, their
use has been hampered by substantial adverse maternal side
effects, which range from the frequent but self-limiting side
effects, such as tremor, anxiety, palpitations, nausea, and
headaches [1], to the rare but serious side effects, such as
pulmonary edema, myocardial ischemia, cardiac failure, and
even maternal death [2]. They also cause metabolic side
effects, such as hyperglycemia, because of nonspecific acti-
vation of adrenergic receptors in the liver, resulting in
hyperinsulinemia [3] and, consequently, hypokalemia from
insulin-induced intracellular shift of potassium. In the case
presented here, the patient experienced severe cardiopulmo-
nary side effects after receiving Ritodrine, includingtachycardia, tachypnea, tremor, anxiety, and palpitations. We
reluctantly discontinued the b2-agonist regimen and shifted to
atosiban, which proved to be effective.
One study was designed to present successful tocolytic
treatment with the specific oxytocin receptor antagonist atosi-
ban in the management of extreme preterm labor in the 18th
week through 24th week of gestation [4]. Another study
involving a larger number of patients (n¼ 501) has shown that
atosiban provided a significantly better tocolytic effect at or
beyond 28 weeks’ gestation when compared with placebo [5].
No study has demonstrated that atosiban could effectively
prevent inevitable or threatened abortion before 18 weeks’
gestation. Studies concerning the myometrial oxytocin receptor
density during the course of pregnancy have shown an approx-
imately sixfold increase between 13 weeks and 17 weeks of
pregnancy compared with the receptor density in the nonpreg-
nant uterus. There is a further increase in myometrial oxytocin
receptor density to nearly 80-fold by term, with an additional
increase during parturition [6]. More recent findings in both the
nonpregnant uterus and the uterus during the early stages of
pregnancy have shown that significantly more oxytocin recep-
tors are expressed than was previously assumed [7]. Theoreti-
cally, an oxytocin antagonist could exert its effect on the uterus
and abate contractions in the very early second trimester. It
might be an alternative when traditional tocolytic therapies,
such as b-agonists, steroids, and progesterone, are ineffective.References
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